Stifel Nicolaus Sticks to Their Buy Rating for Trupanion

By Austin Angelo

In a report released today, Jonathan Block from Stifel Nicolaus reiterated a Buy rating on Trupanion (NYSE: TRUP), with a price target of $34. The company’s shares closed yesterday at $31.27.

According to, Block is a 5-star analyst with an average return of 21.1% and a 71.4% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Alnylam Pharma.

Currently, the analyst consensus on Trupanion is Strong Buy and the average price target is $37.33, representing a 19.4% upside.

In a report issued on February 8, Northland Securities also reiterated a Buy rating on the stock with a $38 price target.

Based on Trupanion’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $66.55 million and GAAP net loss of $838K. In comparison, last year the company earned revenue of $51.34 million and had a GAAP net loss of $1.72 million.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2017, Ian Moffat, the COO of TRUP sold 7,000 shares for a total of $210,420.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider. It provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The company operates its business through two segments: Subscription and Others.